Data Sheet 1_Comparative efficacy of lipid-lowering therapies on the cardio-renal-metaboli

A systematic review and Bayesian network meta-analysis of 20 randomized controlled trials comparing lipid-lowering agents for cardio-renal-metabolic outcomes in diabetic kidney disease. The analysis, authored by Jun Luo, was registered with PROSPERO and includes results up to May 10, 2025. The dataset is a 6.5 MB document summarizing the study's background, methods, and findings.

Use Cases

• Compare the efficacy of statins and fibrates on cholesterol levels based on reported mean differences and confidence intervals.
• Analyze the impact of specific drugs like Atorvastatin and Fenofibrate on cardiovascular event rates in hyperlipidemic DKD patients.
• Evaluate the renal effects of lipid-lowering therapies based on changes in the Urine Albumin-to-Creatinine Ratio (UACR).
• Conduct secondary analysis or meta-regression using the summary data from the 20 included RCTs.

Strengths

• Analysis is based on 20 randomized controlled trials, providing a structured evidence base.
• Results include specific mean differences and 95% confidence intervals for outcomes like Total Cholesterol and LDL-C.
• The document is shared under a permissive CC-BY-4.0 license, allowing for reuse.

Limitations

• The primary data is a summary document (DOCX); the underlying trial-level data is not provided.
• Row count and column-level documentation for any potential supplementary data are unknown.
• The analysis scope is limited to trials identified up to May 10, 2025.

Provenance

Source

figshare, author Jun Luo.

Collection Method

Systematic review and Bayesian network meta-analysis of RCTs from PubMed, Embase, Web of Science, and Cochrane Library.

Time Range

Trials included up to May 10, 2025.

Freshness

Last updated 2026-05-29 04:46:51.